SCYX vs. QTTB, RLMD, CNTB, ASRT, ORMP, ETON, PMVP, ANVS, CUE, and MIST
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Q32 Bio (QTTB), Relmada Therapeutics (RLMD), Connect Biopharma (CNTB), Assertio (ASRT), Oramed Pharmaceuticals (ORMP), Eton Pharmaceuticals (ETON), PMV Pharmaceuticals (PMVP), Annovis Bio (ANVS), Cue Biopharma (CUE), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.
SCYNEXIS (NASDAQ:SCYX) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.
SCYNEXIS has a net margin of 72.18% compared to Q32 Bio's net margin of 0.00%. SCYNEXIS's return on equity of 112.89% beat Q32 Bio's return on equity.
SCYNEXIS has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500.
In the previous week, Q32 Bio had 8 more articles in the media than SCYNEXIS. MarketBeat recorded 11 mentions for Q32 Bio and 3 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.45 beat Q32 Bio's score of 1.17 indicating that SCYNEXIS is being referred to more favorably in the media.
SCYNEXIS has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
SCYNEXIS received 501 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 100.00% of users gave Q32 Bio an outperform vote while only 70.24% of users gave SCYNEXIS an outperform vote.
SCYNEXIS presently has a consensus target price of $15.00, indicating a potential upside of 538.30%. Q32 Bio has a consensus target price of $49.67, indicating a potential upside of 91.17%. Given SCYNEXIS's higher possible upside, research analysts plainly believe SCYNEXIS is more favorable than Q32 Bio.
54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 2.9% of SCYNEXIS shares are owned by insiders. Comparatively, 16.1% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
SCYNEXIS beats Q32 Bio on 12 of the 19 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
